Rising Prevalence Of Chronic Diseases Propelling Growth In Branded Generics Market: A Key Driver Powering Branded Generics Market Growth In 2025

The Branded Generics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

How Big Is the Branded Generics Market Size Expected to Be by 2034?
The market size of branded generics has witnessed a robust growth recently. The projection is that it will increase from $363.49 billion in 2024 to $397.19 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 9.3%. Factors such as cost effectiveness, patent terminations, market outreach and accessibility, government schemes, and healthcare transformations have contributed to this growth in the past.

The size of the branded generics market is anticipated to expand swiftly in the upcoming years, reaching $601.4 billion in 2029 with a compound annual growth rate (CAGR) of 10.9%. Factors contributing to this expected growth during the forecast period include increased demand for generic biologics, escalating chronic diseases, growth in emerging markets, and a focus on biosimilars. Foreseen trends during this period encapsulate strategic alliances and partnerships, technological progression, emphasis on chronic diseases, market consolidation, and a focus towards a patient-centered approach.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7186

What Are the Emerging Segments Within the Branded Generics Market?
The branded generics market covered in this report is segmented -

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs
2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration
3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:
1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds
2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues
3) By Hormones: Corticosteroids, Thyroid Hormones
4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers
5) By Lipid Lowering Drugs: Statins, Fibrates
6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics
8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs
9) By Other Drugs: Analgesics, Antibiotics, Antivirals

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

What Long-Term Drivers Are Shaping Branded Generics Market Trends?
The escalating occurrence of lasting illnesses is anticipated to propel the expansion of the branded generics market. Chronic ailments, while usually not fully curable, can be managed and moderated. An increase in such diseases can be attributed to factors such as the rising consumption of tobacco, inadequate nutrition, lack of physical activity, and overconsumption of alcohol, among others. Globally, consumers are favoring branded generics for addressing chronic diseases due to their affordability compared to regular medicines. For example, the World Health Organization (WHO) 2022 Highlights reported in September 2022 that noncommunicable diseases (NCDs) or chronic diseases were responsible for 41 million deaths, which accounted for 74% of global fatalities. Consequently, the growing prevalence of chronic ailments is projected to stimulate the demand for branded generics in the upcoming period.

Who Are the Top Competitors in Key Branded Generics Market Segments?
Major companies operating in the branded generics market include Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

What Branded Generics Market Trends Are Gaining Traction Across Different Segments?
A significant trend currently observed in the branded generics market is the formation of strategic alliances. In this scenario, companies producing branded generics are collaborating with related companies to capitalize on mutual resources and penetrate new markets. As an example, in September 2024, a cooperation was forged between Biocon Ltd., an Indian pharmaceutical business, and Tabuk Pharmaceuticals. Biocon undertakes the task of developing and manufacturing GLP-1 products tailored for diabetes treatment, thus promising high-grade biopharmaceuticals. In contrast, Tabuk Pharmaceuticals possesses the marketing authorization rights and is entrusted with the task of managing the registration, importation, and promotion of these products, particularly focusing on the Middle East and Saudi Arabia. This partnership also includes scope for growth into other GLP products beyond the initially offered, thus paving the way for offering a wider spectrum of diabetes treatments. The mutual goal of this partnership is to offer innovative health solutions boosting the health conditions of patients residing in Saudi Arabia and nearby regions. This resonates with the commitment of both companies towards enhancing healthcare accessibility. Tabuk Pharmaceuticals is a pharmaceutical company based in Saudi Arabia trading in both branded and generic pharmaceutical products.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Which Regions Are Becoming Hubs for Branded Generics Market Innovation?
North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Branded Generics Market?
2. What is the CAGR expected in the Branded Generics Market?
3. What Are the Key Innovations Transforming the Branded Generics Industry?
4. Which Region Is Leading the Branded Generics Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.